LakeShore Biopharma Co., Ltd (NYSE:LSBCF) — Market Cap & Net Worth
Market Cap & Net Worth: LakeShore Biopharma Co., Ltd (LSBCF)
LakeShore Biopharma Co., Ltd (NYSE:LSBCF) has a market capitalization of $2.76 Million ($2.76 Million) as of September 17, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #29700 globally and #6049 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LakeShore Biopharma Co., Ltd's stock price $0.07 by its total outstanding shares 41212693 (41.21 Million). Also see LakeShore Biopharma Co., Ltd total assets for a full breakdown of the balance sheet.
LakeShore Biopharma Co., Ltd Market Cap History: 2025 to 2026
LakeShore Biopharma Co., Ltd's market capitalization history from 2025 to 2026. Data shows growth from $34.62 Million to $2.76 Million (0.00% CAGR). Also see cash flow conversion of LakeShore Biopharma Co., Ltd for how efficiently the company converts equity into cash flow.
LakeShore Biopharma Co., Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LakeShore Biopharma Co., Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check LakeShore Biopharma Co., Ltd (LSBCF) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.06x
LakeShore Biopharma Co., Ltd's market cap is 0.06 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $34.62 Million | $614.96 Million | -$99.98 Million | 0.06x | N/A |
Competitor Companies of LSBCF by Market Capitalization
Companies near LakeShore Biopharma Co., Ltd in the global market cap rankings as of September 17, 2026. Review how tangible is LakeShore Biopharma Co., Ltd's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to LakeShore Biopharma Co., Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
LakeShore Biopharma Co., Ltd Historical Marketcap From 2025 to 2026
Between 2025 and today, LakeShore Biopharma Co., Ltd's market cap moved from $34.62 Million to $ 2.76 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.76 Million | -92.02% |
| 2025 | $34.62 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of LakeShore Biopharma Co., Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.76 Million USD |
| MoneyControl | $2.76 Million USD |
| MarketWatch | $2.76 Million USD |
| marketcap.company | $2.76 Million USD |
| Reuters | $2.76 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About LakeShore Biopharma Co., Ltd
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies vaccine, which is in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS… Read more